TSG-6 Protein Reduces Inflammation, Tissue Breakdown, and Pain Signals in Degenerating Spinal Discs

What the researchers found

TSG-6 overexpression in IL-1β-stimulated human nucleus pulposus cells produced multiple beneficial effects: it inhibited inflammatory cytokines (TNF-α, IL-8, IL-6), promoted protective extracellular matrix synthesis (increased collagen II and aggrecan, decreased MMP-3), increased sulfated glycosaminoglycan (sGAG) production, and reduced expression of pain-related molecules including CGRP, Substance P, and nerve growth factor.

All of these effects were mediated through activation of the PI3K/Akt signaling pathway. Both TSG-6 and IL-1β were found to be significantly elevated in degenerated versus normal disc tissue, and IL-1β treatment increased TSG-6 expression in disc cells, suggesting a natural feedback mechanism.

Why it matters

Disc degeneration is a leading cause of chronic pain, and current treatments are limited to symptom management or surgery. Finding that TSG-6 can simultaneously reduce inflammation, protect disc structure, and suppress pain signals through a single pathway makes it an attractive therapeutic target. The ability to modulate neuropeptides like CGRP and Substance P — key mediators of disc-related pain — is particularly relevant.

How the study worked

Researchers compared TSG-6 and IL-1β expression in normal and degenerated human cervical disc tissue using qRT-PCR and ELISA. Human nucleus pulposus cells were treated with IL-1β (10 ng/mL) and then TSG-6 was overexpressed. Effects on inflammatory markers, extracellular matrix proteins, pain-related molecules, and PI3K/Akt signaling were assessed using qRT-PCR and western blot. sGAG synthesis was also measured.

What this study cannot tell us

The study was conducted entirely in vitro using cultured human disc cells, which may not fully replicate the complex in vivo disc environment. No animal model or clinical data were presented. The IL-1β concentration used (10 ng/mL) may not reflect physiological levels. TSG-6 overexpression was achieved through artificial means, and therapeutic delivery to disc tissue in vivo would face significant challenges. Long-term effects and dose-response relationships were not explored.

How to read the evidence

This is an in vitro mechanistic study using cultured human nucleus pulposus cells. While it provides clear mechanistic insights, the findings have not been validated in animal models or clinical settings.

When this study was published

Published in 2022, this study adds to the growing understanding of TSG-6's therapeutic potential in musculoskeletal diseases.

The bigger picture

This study connects anti-inflammatory biology with pain neuroscience through neuropeptides. CGRP and Substance P are well-established pain mediators — CGRP is already a validated drug target for migraine (with approved CGRP antibodies and antagonists). Finding that TSG-6 can reduce these neuropeptides in disc cells suggests a new approach to disc-related pain that addresses both structural degeneration and pain signaling simultaneously.

Questions still open

• Could TSG-6 delivery to degenerating discs reduce both structural damage and pain in animal models?
• Is the reduction in CGRP and Substance P sufficient to produce meaningful pain relief in patients?
• How could TSG-6 be delivered therapeutically to disc tissue — via injection, gene therapy, or cell-based approaches?

Common questions

Read the original research

TSG-6 inhibits IL-1β-induced inflammatory responses and extracellular matrix degradation in nucleus pulposus cells by activating the PI3K/Akt signaling pathway.

Journal of orthopaedic surgery and research, 17(1), 572

Citation

Wu, Bing; Guo, Xiaojin; Yan, Xiujie; Tian, Zikai; Jiang, Wei; He, Xin. (2022). TSG-6 inhibits IL-1β-induced inflammatory responses and extracellular matrix degradation in nucleus pulposus cells by activating the PI3K/Akt signaling pathway.. Journal of orthopaedic surgery and research, 17(1), 572. https://doi.org/10.1186/s13018-022-03468-9